Centrifugal Blood Pumps Market Size, Share & Forecast Analysis to 2030

The global centrifugal blood pumps market size was valued at around USD 100 million in 2025 and projected to grow at a significant CAGR of around 5% during the forecast period from 2026 to 2030. The market is experiencing steady growth, driven by the increasing prevalence of cardiovascular diseases, rising adoption of extracorporeal membrane oxygenation (ECMO), and growing demand for advanced mechanical circulatory support systems. The North America leads the market due to its advanced healthcare infrastructure and high volume of cardiac procedures, while Asia Pacific is expected to witness the fastest growth supported by expanding healthcare investments and increasing access to specialized cardiac care.

Market Snapshot:

Key Insights:

• The centrifugal blood pumps market is expanding steadily due to rising cardiovascular disease prevalence and increasing demand for mechanical circulatory support systems.
• North America dominates the market, supported by advanced healthcare infrastructure, high cardiac surgery volumes, and widespread ECMO technology adoption.
• Extracorporeal centrifugal blood pumps account for the largest market share because of their extensive use in ECMO and cardiopulmonary bypass procedures.
• Electronic centrifugal blood pumps lead the design segment by offering precise blood flow control, real-time monitoring, and enhanced patient safety.

Key Factors Driving the Centrifugal Blood Pumps Market Growth

The rising prevalence of cardiovascular diseases and the increasing demand for advanced mechanical circulatory support systems are key factors driving the growth of the centrifugal blood pumps market. The growing incidence of heart failure, cardiogenic shock, and other life-threatening cardiac conditions has significantly increased the use of centrifugal blood pumps in cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), and ventricular assist device (VAD) procedures. Compared to conventional roller pumps, centrifugal blood pumps offer superior blood flow regulation, reduced hemolysis, and improved patient safety, making them an essential component of modern cardiac surgeries and critical care. Furthermore, the increasing number of complex cardiovascular procedures, coupled with the expansion of specialized cardiac care centers, continues to strengthen market demand.

Another major growth driver is the ongoing technological advancement in extracorporeal life support (ECLS) and ECMO systems, which is improving the efficiency and reliability of centrifugal blood pump technologies. Manufacturers are focusing on developing compact, portable, and magnetically levitated pump systems that minimize blood trauma while enhancing clinical performance and ease of use. For instance, in March 2026, Getinge received CE Mark approval for Cardiohelp II, its next-generation ECLS platform, featuring advanced patient monitoring, integrated electronic gas management, and enhanced workflow support for ECMO therapy. This development reflects the industry’s continued investment in innovative centrifugal blood pump solutions designed to improve patient outcomes and expand the adoption of mechanical circulatory support technologies across hospitals and critical care settings.

Key Growth Drivers

• Rising investments in ECMO and extracorporeal life support infrastructure across emerging economies are creating substantial opportunities for centrifugal blood pump manufacturers.
• Continuous innovation in compact, magnetically levitated, and digitally integrated blood pump technologies is expanding adoption across advanced cardiac care settings.
• Increasing use of temporary mechanical circulatory support during high-risk cardiac surgeries is generating long-term growth opportunities for market participants.

Centrifugal Blood Pumps Restraining Factors

The high cost of centrifugal blood pump systems and associated extracorporeal life support equipment remains a significant restraint for the centrifugal blood pumps market. Advanced ECMO and cardiopulmonary bypass systems require substantial capital investment, specialized consumables, and ongoing maintenance, making them less accessible for small and mid-sized healthcare facilities. Additionally, the high procedural costs and limited reimbursement in several developing countries can restrict the widespread adoption of these technologies, particularly in resource-constrained healthcare systems.

Another major challenge is the requirement for highly trained healthcare professionals and the risk of procedure-related complications. The safe operation of centrifugal blood pumps during ECMO and cardiac surgery demands experienced perfusionists, intensivists, and specialized clinical teams. Inadequate training or improper device management can increase the risk of complications such as bleeding, thrombosis, infection, and hemolysis, limiting their use in healthcare facilities with limited expertise. Furthermore, stringent regulatory approval processes and lengthy product validation timelines can delay the commercialization of innovative blood pump technologies.

Future Opportunities Reshaping the Centrifugal Blood Pumps Market’s Evolution

The expanding availability of advanced cardiac care services and the increasing adoption of extracorporeal life support (ECLS) therapies are creating substantial opportunities for the centrifugal blood pumps market. As hospitals continue to strengthen intensive care capabilities and establish dedicated ECMO programs, the demand for high-performance centrifugal blood pumps is expected to rise. Furthermore, increasing healthcare investments in emerging economies and the growing need for rapid circulatory support during complex cardiac procedures are encouraging wider adoption of these systems across both public and private healthcare facilities.

Another significant opportunity lies in the development of next-generation centrifugal blood pump technologies for advanced heart failure management. Manufacturers are increasingly investing in innovative mechanical circulatory support systems and clinical research to improve patient outcomes through earlier intervention. For instance, in October 2024, Abbott initiated the TEAM-HF clinical trial to evaluate whether earlier use of its HeartMate 3™ left ventricular assist device, guided by CardioMEMS™ pulmonary artery pressure monitoring, can improve outcomes in patients with worsening heart failure. This initiative highlights the growing emphasis on advancing centrifugal-flow LVAD technologies and expanding their adoption in the treatment of advanced heart failure.

Key Growth Opportunities

• Expanding ECMO and mechanical circulatory support programs across hospitals are creating strong demand for advanced centrifugal blood pump technologies.
• Increasing clinical adoption of centrifugal-flow ventricular assist devices for advanced heart failure is opening new long-term market growth opportunities.
• Ongoing innovation in compact, magnetically levitated, and digitally integrated blood pumps is enabling broader applications in critical care and cardiac surgery.

Industry Trends Shaping the Global Centrifugal Blood Pumps Market

The adoption of magnetically levitated and digitally integrated centrifugal blood pumps is emerging as a major trend in the centrifugal blood pumps market. Healthcare providers are increasingly preferring advanced pump systems that reduce hemolysis, improve biocompatibility, and deliver precise blood flow during ECMO, cardiopulmonary bypass, and ventricular assist procedures. At the same time, manufacturers are incorporating intelligent monitoring, compact designs, and automated control features to enhance patient safety, clinical efficiency, and ease of operation in critical care settings.

Another significant trend is the growing emphasis on portable extracorporeal life support technologies to support emergency transport and intensive care applications. For instance, in July 2024, Eurosets announced the successful clinical use of its Colibrì third-generation ECMO system at Martinique University Hospital. The system incorporates a magnetically levitated centrifugal pump and is designed to provide neonatal, pediatric, and adult extracorporeal life support, highlighting the industry’s focus on compact and high-performance blood pump technologies.

Market Segments Insights:

By Design Type: The Electronics Segment Dominated the Global Centrifugal Blood Pumps Market

The global centrifugal blood pumps market is bifurcated into design type, product type, application, end-user, and geography. On the basis of design type, the electronic segment holds the largest share of the market due to its ability to deliver precise blood flow control, real-time monitoring, and automated performance adjustments during complex cardiac procedures. These systems are extensively used in extracorporeal membrane oxygenation (ECMO), cardiopulmonary bypass (CPB), and ventricular assist device (VAD) applications, where accuracy and patient safety are critical. Electronic blood pumps also reduce the risk of hemolysis and improve clinical outcomes through advanced sensors, digital interfaces, and integrated alarm systems.

The segment’s dominance is further supported by the increasing adoption of technologically advanced mechanical circulatory support systems in hospitals and specialized cardiac centers. Growing investments in critical care infrastructure, rising demand for minimally invasive cardiac procedures, and continuous innovations such as magnetically levitated pumps and intelligent monitoring technologies are accelerating the deployment of electronically controlled centrifugal blood pumps. These advantages are expected to help the electronic segment maintain its leading position throughout the forecast period.

By Product Type: The Extracorporeal Pumps Sub-category Holds the Largest Share of Global Centrifugal Blood Pumps Market

On the basis of product type, the global centrifugal blood pumps market is further segmented into implantable and extracorporeal centrifugal blood pumps. The extracorporeal centrifugal blood pumps segment dominates the market due to its extensive use in extracorporeal membrane oxygenation (ECMO), cardiopulmonary bypass (CPB), and temporary mechanical circulatory support procedures. These pumps are widely adopted in hospitals and specialized cardiac centers because they provide stable blood flow, minimize hemolysis, and enable efficient circulation during complex cardiac surgeries and critical care interventions. Their broad clinical applications and increasing utilization in emergency and intensive care settings continue to support the segment’s leading market position.

The segment’s dominance is further supported by continuous innovation in extracorporeal circulation technologies and regulatory approvals that enhance the efficiency of cardiopulmonary bypass procedures. For instance, in March 2023, LivaNova received U.S. FDA 510(k) clearance for its Essenz™ Heart-Lung Machine, enabling the commercial launch of its next-generation Essenz™ Perfusion System for cardiopulmonary bypass procedures. The system combines advanced monitoring, patient-tailored perfusion capabilities, and streamlined workflow features, reflecting the industry’s growing focus on improving extracorporeal circulation and supporting the adoption of advanced centrifugal blood pump technologies.

Global Centrifugal Blood Pumps Market Segmentation:

By Design Type:

• Electronic
• Mechanical

By Product Type:

• Implantable Centrifugal Blood Pumps
• Extracorporeal Centrifugal Blood Pumps

By Application:

• Cardiopulmonary Bypass (CPB)
• Extracorporeal Membrane Oxygenation (ECMO)
• Ventricular Assist Devices (VAD)

By End-User:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Regional Analysis: The North America Leading the Global Centrifugal Blood Pumps Market

Geographically, the North America dominates the global centrifugal blood pumps market owing to its advanced healthcare infrastructure, high volume of cardiothoracic surgeries, and widespread adoption of extracorporeal membrane oxygenation (ECMO) and ventricular assist devices (VADs). The region also benefits from a high prevalence of cardiovascular diseases, favorable reimbursement policies, and the presence of leading medical device manufacturers that continuously invest in innovative mechanical circulatory support technologies. Additionally, the availability of specialized cardiac centers and experienced perfusion teams continues to drive the adoption of advanced centrifugal blood pump systems.

The region’s leadership is further reinforced by a supportive regulatory environment that facilitates the introduction of next-generation circulatory support technologies. For instance, in January 2024, the U.S. FDA granted 510(k) clearance to Abbott’s CentriMag™ Acute Circulatory Support System, a long-term (>6 hours) ECMO blood pump system designed to provide temporary mechanical circulatory support for critically ill patients. This regulatory approval highlights the continued advancement of centrifugal blood pump technologies in the United States and strengthens North America’s position as the leading regional market.

Competitive Analysis:

The centrifugal blood pumps market is characterized by intense competition among established medical device manufacturers that focus on product innovation, technological advancements, and expanding their mechanical circulatory support portfolios. Companies are investing in magnetically levitated pump technologies, advanced perfusion systems, portable ECMO platforms, and digitally integrated monitoring solutions to improve clinical outcomes and strengthen their competitive position. Strategic collaborations, geographic expansion, and continuous research and development remain key strategies for enhancing market presence.

Leading companies are also emphasizing product quality, regulatory compliance, and customized solutions for cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), and ventricular assist device (VAD) applications. Their focus on improving hemocompatibility, minimizing blood trauma, and enhancing workflow efficiency enables them to meet the growing demand for advanced circulatory support technologies. Key players operating in the market include Medtronic plc, Abbott Laboratories, Terumo Corporation, Getinge AB, and LivaNova PLC.

Key Companies:

• Medtronic plc
• Abbott Laboratories
• Terumo Corporation
• Getinge AB
• LivaNova PLC
• Fresenius Medical Care AG
• Xenios AG (A Fresenius Medical Care Company)
• Braile Biomedica
• Senko Medical Instrument Mfg. Co., Ltd.
• EUROSETS S.r.l.

Global Centrifugal Blood Pumps Market Outlook

• Growing adoption of ECMO and temporary mechanical circulatory support therapies will continue to drive demand for advanced centrifugal blood pump systems.
• Technological advancements in magnetically levitated pumps, digital monitoring, and compact designs are expected to improve clinical outcomes and expand product adoption.
• Increasing investments in specialized cardiac care centers and critical care infrastructure across emerging economies will create significant growth opportunities.
• Rising clinical research and innovation in ventricular assist devices and extracorporeal life support technologies will support sustained market expansion during the forecast period.

Frequently Asked Questions About the Centrifugal Blood Pumps Market